0000899243-21-001378.txt : 20210111
0000899243-21-001378.hdr.sgml : 20210111
20210111175909
ACCESSION NUMBER: 0000899243-21-001378
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210108
FILED AS OF DATE: 20210111
DATE AS OF CHANGE: 20210111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leggett Thomas
CENTRAL INDEX KEY: 0001774690
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39200
FILM NUMBER: 21521844
MAIL ADDRESS:
STREET 1: C/O AXCELLA HEALTH INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701541
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET, 10TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-417-5868
MAIL ADDRESS:
STREET 1: ONE MAIN STREET, 10TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aset Therapeutics, Inc.
DATE OF NAME CHANGE: 20170321
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-08
0
0001701541
Black Diamond Therapeutics, Inc.
BDTX
0001774690
Leggett Thomas
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 10TH FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Chief Financial Officer
Common Stock
2021-01-08
4
M
0
3000
10.86
A
3000
D
Common Stock
2021-01-08
4
S
0
3000
33.94
D
0
D
Stock Option (Right to Buy)
10.86
2021-01-08
4
M
0
3000
0.00
D
2029-09-08
Common Stock
3000
218171
D
Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $34.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
/s/ Brent Hatzis-Schoch, as Attorney-in-Fact
2021-01-11